Medical stock Pacs Group is climbing up the right side of a cup base with a buy point of 43.08.

SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) today announced that independently operated subsidiaries of the Company have acquired the operations of three post-acute care facilities, two located in Alaska and one in Idaho, representing a total of 230 beds. The facilities are located in the Kenai Peninsula region of Alaska and the Boise metropolitan area of Idaho. The Company acquired the real estate associated with the two Alaska facilities, while the.

Utah-based Crewe Advisors bought 1,035,747 PACS shares in the fourth quarter for an estimated $22.72 million. Meanwhile, the quarter-end PACS position value rose by $67.19 million, reflecting both trading and stock price changes.

PACS Group, Inc. (PACS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) announced today that Jason Murray, Chairman and Chief Executive Officer, and Mark Hancock, Executive Vice President and Interim Chief Financial Officer, will present at the annual J.P. Morgan Healthcare Conference in San Francisco. The presentation audio will be webcast live on Tuesday, January 13, 2026, at 5:15 pm Pacific Time. To access the live webcast, please visit the Investor Relations section of PACS's website at https://ir.p.

PACS Group (NYSE: PACS - Get Free Report) and Ethema Health (OTCMKTS:GRST - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Volatility and Risk PACS Group has a beta

Cannlabs (OTCMKTS:CANL - Get Free Report) and PACS Group (NYSE: PACS - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Risk and Volatility Cannlabs has a beta of 1.75,

PACS Group (NYSE: PACS - Get Free Report) and iSpecimen (NASDAQ: ISPC - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Valuation and Earnings This table compares PACS Group and

PACS Group, Inc. (NYSE: PACS - Get Free Report) has been given an average recommendation of "Hold" by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the

Evelyn Dilsaver acquired $500,000 worth of PACS Group Stock. Dilsaver is a member of Pacs Group's Board of Directors.